Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.
What is known and objectives: Adverse drug reactions (ADR) related to the treatment of visceral leishmaniasis (VL) can cause severe clinical complications. We report a case series of ADR in hospitalized VL patients on meglumine antimoniate (MA). Case description: Seven cases of patients taking MA ha...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 45; no. 3; pp. 573 - 577 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | What is known and objectives: Adverse drug reactions (ADR) related to the treatment of visceral leishmaniasis (VL) can cause severe clinical complications. We report a case series of ADR in hospitalized VL patients on meglumine antimoniate (MA). Case description: Seven cases of patients taking MA had at least one objective evidence for suspected ADR, including electrocardiographic, laboratory or clinical alteration. What is new and conclusion: Meglumine antimoniate is highly toxic. Adherence to treatment guidelines is important. Pharmacists working in multidisciplinary teams may contribute to early detection and management of MA therapy‐related ADR. |
|---|